2 pharmaceutical equipment enterprises in 2020 half-yearly report happy, the industry shows a good development trend.

Pharmaceutical Network Market Analysis: July-August, it is the period of intensive disclosure of listed companies, performance-led market probability is rising.
the author according to the incomplete statistics of public information, there are currently 2 pharmaceutical equipment listed companies to disclose the 2020 half-year report, and the performance is expected.
this also shows to a certain extent that china's pharmaceutical equipment industry in the first half of this year showed a good development trend, the head of enterprises to increase the stability.
2 pharmaceutical equipment enterprises 2020 half-year lying happy, the industry showed a good development trend (source: pharmaceutical network) 2 pharmaceutical equipment companies disclosed the half-year lying current, Canaan Technology is expected to 2020 first half profit of 27.2618 million yuan - 32.7141 million yuan, 2019 the company's profit in the same period 18.1745 million yuan, up 50%-80% year-on-year.
Canaan Technology's main business for pharmaceutical equipment, is well-known in China solid preparations intelligent factory overall solution suppliers.
Company was listed on the Shenzhen Stock Exchange GEM on December 31, 2014.
total assets of Canaan Technology in 2019 amounted to RMB1,517 million, an increase of 11.42 percent over the previous year.
Canaan Technology said that the main reason for the change in performance is the reporting period, the company actively take effective measures, one-handed lying against epidemic prevention, one-handed production, to protect some downstream customers pharmaceutical enterprises and logistics industry epidemic-related products supply.
the company's steady sales growth, while operating efficiency, to ensure a stable growth in business performance.
integrated pharmaceutical equipment service provider Dongfulong's performance in the first half of this year is expected to double in 2019 on the basis of another accelerated growth, is expected to make a profit of 164 million yuan - 176 million yuan in the first half of this year, the same period last year profit of 382.274 million yuan, an increase of 330%-360% year-on-year.
Dongfulong broke into the IPO on February 1, 2011 and landed on the GEM.
it is worth mentioning that the company's total assets have grown from 539 million yuan in 2009 to 5.209 billion yuan by the end of 2019, an increase of nearly nine times in 10 years.
companies said that the first half of this year's rapid growth in performance, due to its reporting period, in accordance with the "systematic, international, digital" development strategy, actively explore the market, pharmaceutical equipment sector and medical technology sector revenue increased year-on-year;
industry shows a good development trend Industry believes that, from the two pharmaceutical machine enterprises in the first half of the performance of the degree of good, the first half of China's pharmaceutical equipment industry as a whole showed a relatively good development trend, the head of enterprises to increase the amount of stability.
demand, in the first half of this year, some pharmaceutical products and epidemic prevention products surged demand, related equipment companies face the challenge of increasing capacity.
the first quarter, affected by the special period, some pharmaceutical machine enterprises due to the resumption of production delay, resulting in equipment delivery and commissioning progress slowed down, the current period sales revenue significantly reduced, the current period of net profit fell significantly.
but with the subsequent resumption of work and resumption of production to accelerate, effectively protect the supply of pharmaceutical products, the business performance of enterprises have basically been stable growth.
at the same time, some pharmaceutical machine enterprises because of the flexible use of telecommuting, sales, online services and other models, access to a lot of new orders.
this also reflects the industry's high business climate.
research and development investment, since 2020, pharmaceutical equipment companies in research and development investment is also increasing efforts, and actively expand the market.
now the first quarter of this year, Dongfulong's research and development costs continue to be high investment trend, up 37.76% YoY; Chutian Technology related to the relevant person in charge said that Chutian Technology to blood products, vaccines, Chinese medicine and other equipment to increase research and development investment, will further broaden the market, and expected this year's order target, delivery target scored a greater increase;
in May of this year, Canaan Technology announced that it intends to invest 100 million yuan of its own capital to set up a wholly-owned subsidiary of Zhejiang Canaan Health Technology Co., Ltd., with a view to expanding the size of the company's business, enhance the company's overall competitiveness, and better consolidate the "solid preparation intelligent factory overall solution supplier" and large health strategy layout.
it is worth mentioning that the current vaccine sector has attracted the attention of investors, at the same time, the vaccine industry chain upstream and downstream industries, including vaccine filling equipment has also attracted the attention of investors.
investors believe that the relevant filling equipment or ushered in explosive development, Dongfulong and Chutian Technology two pharmaceutical manufacturing equipment manufacturers will become the focus of attention.
at present, Dongfulong said on the interactive platform, the company's pre-potting production line can be used in vaccines, monoantinos, small moleculeheparin, insulin, boric acid and other sterile products production and packaging.
Chutian Technology in response to investors, said the company has the production of vaccine equipment related orders, the specific filling form in the form of customer demand to provide different equipment.
concluding in the long run, with the promotion of medical reform policies such as consistency evaluation and volume procurement, the innovative pharmaceutical industry will develop rapidly.
at the same time with The growing trend of aging in China, the demand for pharmaceutical products gradually expand, the upstream pharmaceutical equipment industry will usher in a good opportunity.
at present, China's pharmaceutical equipment is mainly concentrated in the middle and low-end areas, the future in the high-end field has a larger market development space.
.